---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-343469"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2026-08-11T12:00:14+00:00"
generated_at: "2026-08-11T12:06:00.293419+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Prelude Therapeutics Q2 2026 net loss narrows to $13.9M; cash runway into Q2 2028

## Summary
- Q2 2026 net loss $13.9M ($0.14/share) vs $31.2M ($0.41/share) in Q2 2025.
- Cash, equivalents, restricted cash and marketable securities $155.2M at June 30, 2026; funds ops into Q2 2028.
- R&D expense fell to $16.1M from $25.8M YoY; G&A to $5.0M from $6.4M.
- Plan to initiate Phase 1 of PRT13722 (KAT6A degrader) in HR+ breast cancer in Q4 2026, pending IND.
- Enrollment continues for PRT12396 JAK2V617F inhibitor; mCALR DAC program advancing.

## SEC filing metadata
- accession: 0001193125-26-343469
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2026-08-11T12:00:14+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000119312526343469/0001193125-26-343469-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000119312526343469/prld-20260811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-343469
- JSON: https://secwatch.observer/filing/0001193125-26-343469.json
- Plain text: https://secwatch.observer/filing/0001193125-26-343469.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.